GlassScriptPhysician profile
Sarah Westin
NPI 1386245827
$15,985.81
in general payments reported to CMS, 2019-2025
27 companies · $3,355 in 2025
The $3,355 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,260 · 2022: $3,190 · 2023: $4,615 · 2024: $3,565 · 2025: $3,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $36.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,499.04 |
| Education | $36.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,190.72 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,967.62 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,917.30 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Abbvie INC. | $1,363.99 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,293.60 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Supernus Pharmaceuticals, INC. | $1,288.74 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $883.80 | 2021-2024 | Jornay Pm |
| Neurocrine Biosciences, INC. | $826.80 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $669.07 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $645.84 | 2022-2025 | Austedo Xr, Austedo, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $623.63 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $595.22 | 2022-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $266.35 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $216.78 | 2025 | Jornay Pm |
| Novo Nordisk INC | $193.58 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $158.27 | 2022-2024 | Azstarys |
| Indivior INC. | $156.59 | 2022-2024 | Perseris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $146.72 | 2023-2025 | Rejoyn, Abilify Maintena, Rexulti |
| Vanda Pharmaceuticals INC. | $145.63 | 2022-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $131.02 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $121.51 | 2021-2023 | Belsomra |
| Jazz Pharmaceuticals INC. | $56.14 | 2021 | |
| Eisai INC. | $33.55 | 2021 | |
| Idorsia Pharmaceuticals US INC | $30.63 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $22.52 | 2024 | Xelstrym, Secuado |
| Sage Therapeutics, LLC | $21.25 | 2025 | Zurzuvae |
| Biohaven Pharmaceuticals, INC. | $18.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Westin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.